31 / 62
PARP inhibitors New Trials
Title
ClinicalTrials.gov
Identifier
(Last record update)
Recruitment
Phase
Study in Patients With SCLC of
Veliparib
in
Combination With Topotecan
NCT03227016
(July 21, 2017)
Recruiting
1
Apatinib
for Extensive Stage SCLC After
Second/Third-Line Chemotherapy
NCT02945852
(October 26, 2016)
Recruiting
2
Apatinib
as the Maintenance Therapy for Extensive
Stage SCLC After Combined With Etoposide/Cisplatin
NCT02875457
(August 23, 2016) Not yet recruiting
3
Cisplatin and Etoposide
±
Veliparib
in Treating
Patients With Extensive SCLC or Metastatic Large Cell
Neuroendocrine NSCLC
NCT01642251
(August 28, 2017)
Ongoing, not
recruiting
1-2
ClinicalTrials.gov.
OLAPARIB
: R PHASE II STUDY AS
MAINTENANCE 1L (STOMP)
TALOZAPARIB
: PHASE I STUDY